DRC Bundibugyo Outbreak Exposes Ebola Preparedness Gap
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo has become the largest Ebola outbreak in the country's history and the second-largest Ebola epidemic ever recorded, surpassed only by the 2014–2016 West Africa epidemic.
- Bundibugyo ebolavirus, first identified in Uganda in 2007, is genetically distinct from Zaire ebolavirus (EBOV), and molecular diagnostics optimized for EBOV performed poorly against it early in the outbreak, delaying diagnosis until updated assays were developed and deployed.
- WHO's Technical Advisory Group on Candidate Vaccine Prioritization (TAG-CVP) recommended in May that the licensed Ervebo vaccine should not be used routinely during the Bundibugyo outbreak outside research settings because of insufficient evidence of cross-protection.
- Ervebo (rVSV-ZEBOV) was reassessed by TAG-CVP on July 31, with the group recommending it be evaluated in a Phase 3 trial during the current outbreak — without a preceding Phase 2 study — after emerging lab, immunologic, and animal data suggested possible partial cross-protection against Bundibugyo virus.
- The University of Oxford and the Serum Institute of India have launched the world's first Phase 1 trial of a Bundibugyo-specific vaccine, while Moderna has begun a Phase 1 trial of an mRNA candidate, according to the authors.
- WHO's PARTNERS trial is evaluating remdesivir and the broadly neutralizing monoclonal antibody MBP134, alone and in combination, against Bundibugyo virus disease, while the EBO-PEP study is testing oral obeldesivir as post-exposure prophylaxis in high-risk contacts — with remdesivir offered on a compassionate-use basis to pregnant women and children under 12.
Why it matters: Billions invested after the 2014 West Africa crisis produced rapid diagnostics, a licensed vaccine, and clinical trial networks — but nearly all of it targeted one Ebola species. The second-largest Ebola epidemic in history is now forcing the world to retroactively test and build tools for a virus it could have prepared for in advance, repeating the same single-pathogen blind spot that left influenza-focused systems exposed to COVID-19 and the world flat-footed on mpox.
Ask SkimNews
